**Key Concepts**

1.  **A~2A~R crystallization: selection of different conformational states**

    Structure determination of A~2A~R required the application of novel protein engineering techniques to lock the receptor in defined conformational states and facilitate the growth of crystals that diffract to high resolution.

2.  **Structural determinants of A~2A~R ligand binding and selectivity**

    The atomic resolution structural features of A~2A~R that dictate which ligands it can bind and whether the ligands act as agonists, to promote signaling, or antagonists, to block signaling.

3.  **Ligand-induced activation of A~2A~R**

    The molecular changes that are induced in A~2A~R by agonist binding, which facilitate G protein coupling and ultimately signal transduction.

4.  **Structural diversity of the adenosine receptor family**

    The difference in the primary and ternary structure between the four AR subtypes that is ultimately responsible for their ligand-binding specificity and pharmacological profiles.

Introduction {#s1}
============

Purinergic signaling is predominantly mediated by extracellular purine nucleosides and nucleotides, including adenosine and adenosine triphosphate (ATP), but also by purine bases such as caffeine and xanthine. Purinergic receptors are integral membrane protein that are divided into three classes, P1 (better known as adenosine receptors), P2Y, and P2X (Burnstock, [@B6]). Both P1 and P2Y receptors belong to the G protein-coupled receptor (GPCR) family, whereas P2X receptors are ATP-gated ion channels. Adenosine receptors (ARs) are divided into four subtypes, A~1~, A~2A~, A~2B~, and A~3~ (Fredholm et al., [@B22]), which are broadly expressed in the central nervous system as well as peripheral tissues of the cardiovascular, respiratory, renal, and immune systems (Fredholm et al., [@B22], [@B23]). Extracellular adenosine is the endogenous agonist for all ARs, however differences in the adenosine binding affinity, tissue distribution, expression level and G protein coupling preference between the subtypes gives each a distinct signaling profile (Cieslak et al., [@B17]; Fredholm, [@B21]). A~1~R and A~3~R predominantly activate heterotrimeric G proteins belonging to the Gα~i/o~ family, which inhibit cAMP production by adenylate cyclase, in contrast A~2A~R and A~2B~R predominantly activate Gα~s~ family members, which stimulate cAMP production (Jacobson and Gao, [@B31]). G protein βγ subunits also contribute to signaling through the mitogen-activated protein kinase (MAPK) and phospholipase C (PLC) pathways (Jacobson and Gao, [@B31]). ARs mediate the general cytoprotective functions associated with extracellular adenosine, with some of the key physiological processes regulated by individual subtypes being: sleep, vasoconstriction and inhibition of neurotransmitter release by A~1~R; sleep, angiogenesis, and immunosuppression by A~2A~R; vascular integrity and myocardial preconditioning by A~2B~R; mast cell regulation and myocardial preconditioning by A~3~R (Fredholm et al., [@B23]).

ARs have been proposed as potential targets in a wide variety of pathophysiological conditions, including arrhythmia, ischemia, sleep disorders, pain, dementia, Parkinson\'s, renal failure, asthma, type 2 diabetes, glaucoma, inflammation, and cancer (Jacobson and Gao, [@B31]; Cieslak et al., [@B17]; Sawynok, [@B58]). However, one of the challenges of therapeutic intervention has been targeting individual AR subtypes with sufficient specificity to limit off-target side effects (Chen et al., [@B13]). Medicinal chemistry approaches have been used to develop an array of compounds that exhibit improved subtype specificity (Müller and Jacobson, [@B48]), but very few have been approved for clinical use, due in part to the persistence of undesirable side effects (Chen et al., [@B13]; Glukhova et al., [@B26]). Further improvements in subtype specificity, coupled with the development of allosteric modulators (Gentry et al., [@B25]) that bind outside the orthosteric site, and biased ligands (Kenakin and Christopoulos, [@B34]) that can target a distinct signaling pathway associated with an individual AR subtype, may help to eliminate side effects entirely. Structure-based drug design, which involves *in silico* screening of vast compound libraries against experimentally determined receptor structures, offers huge potential for the development of a new generation of highly selective orthosteric, allosteric, and biased ligands, however, the difficulty of crystallizing GPCRs has, until recently, hindered this approach (Jazayeri et al., [@B32]).

Structure determination of GPCRs is notoriously challenging due to their conformationally dynamic nature and poor thermostability when extracted from the plasma membrane. During the past decade crystallization strategies have been developed that have revolutionized the structural biology of GPCRs, these include protein engineering approaches, such as fusion proteins (Cherezov et al., [@B15]; Chun et al., [@B16]), antibodies (Rasmussen et al., [@B53], [@B52]) and conformational thermostabilization (Magnani et al., [@B43]; Serrano-Vega et al., [@B60]; Shibata et al., [@B61]), as well as technical developments, such as the lipidic cubic phase (LCP) (Landau and Rosenbusch, [@B36]; Caffrey, [@B7]). Human A~2A~R has been at the forefront of this revolution and is now one of the best structurally characterized GPCRs, with more than 30 structures deposited in the protein data bank (PDB; Table [1](#T1){ref-type="table"}). It is the only receptor for which structures of three distinct activation states have been reported, namely the inactive conformation bound to an antagonist or inverse agonist (Jaakola et al., [@B30]), an intermediate-active conformation bound to an agonist (Lebon et al., [@B40]; Xu et al., [@B75]), and the active conformation bound to both an agonist and engineered G protein (Carpenter et al., [@B12]). Crystallization of the other AR subtypes has proved more difficult and it is only during the past year that structures of A~1~R have been published (Cheng et al., [@B14]; Glukhova et al., [@B26]). Significantly, these have provided the first atomic resolution insight in to the molecular determinants of ligand binding specificity in different AR subtypes.

###### 

Adenosine receptor X-ray crystal structures.

  **Receptor subtype**   **Conformational state**   **Ligand class**   **Ligand name**                         **Fusion protein**   **Thermostabilized**   **Binding partner**   **Resolution (Å)**   **PDB code**   **References**
  ---------------------- -------------------------- ------------------ --------------------------------------- -------------------- ---------------------- --------------------- -------------------- -------------- ------------------------------
  A~1~                   Inactive                   Antagonist         DU172[^a^](#TN1){ref-type="table-fn"}   BRIL                 No                     None                  3.2                  [5UEN](5UEN)   Glukhova et al., [@B26]
                         Inactive                   Antagonist         PSB36                                   BRIL                 Yes                    None                  3.3                  [5N2S](5N2S)   Cheng et al., [@B14]
  A~2A~                  Inactive                   Inverse agonist    ZM241385                                T4L                  No                     None                  2.6                  [3EML](3EML)   Jaakola et al., [@B30]
                         Inactive                   Inverse agonist    ZM241385                                None                 Yes                    None                  3.3                  [3PWH](3PWH)   Doré et al., [@B19]
                         Inactive                   Antagonist         XAC                                     None                 Yes                    None                  3.3                  [3REY](3REY)   Doré et al., [@B19]
                         Inactive                   Antagonist         Caffeine                                None                 Yes                    None                  3.6                  [3RFM](3RFM)   Doré et al., [@B19]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 No                     None                  1.8                  [4EIY](4EIY)   Liu et al., [@B41]
                         Inactive                   Antagonist         T4G[^b^](#TN2){ref-type="table-fn"}     None                 Yes                    None                  3.3                  [3UZA](3UZA)   Congreve et al., [@B18]
                         Inactive                   Antagonist         T4E[^b^](#TN2){ref-type="table-fn"}     None                 Yes                    None                  3.3                  [3UZC](3UZC)   Congreve et al., [@B18]
                         Inactive                   Inverse agonist    ZM241385                                None                 No                     Fab2823               2.7                  [3VG9](3VG9)   Hino et al., [@B29]
                         Inactive                   Inverse agonist    ZM241385                                None                 No                     Fab2823               3.1                  [3VGA](3VGA)   Hino et al., [@B29]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 Yes                    None                  1.7                  [5IU4](5IU4)   Segala et al., [@B59]
                         Inactive                   Antagonist         6DY[^b^](#TN2){ref-type="table-fn"}     BRIL                 Yes                    None                  1.9                  [5IU7](5IU7)   Segala et al., [@B59]
                         Inactive                   Antagonist         6DZ[^b^](#TN2){ref-type="table-fn"}     BRIL                 Yes                    None                  2.0                  [5IU8](5IU8)   Segala et al., [@B59]
                         Inactive                   Antagonist         6DX[^b^](#TN2){ref-type="table-fn"}     BRIL                 Yes                    None                  2.2                  [5IUA](5IUA)   Segala et al., [@B59]
                         Inactive                   Antagonist         6DV[^b^](#TN2){ref-type="table-fn"}     BRIL                 Yes                    None                  2.1                  [5IUB](5IUB)   Segala et al., [@B59]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 No                     None                  2.5                  [5K2A](5K2A)   Batyuk et al., [@B5]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 No                     None                  2.5                  [5K2B](5K2B)   Batyuk et al., [@B5]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 No                     None                  1.9                  [5K2C](5K2C)   Batyuk et al., [@B5]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 No                     None                  1.9                  [5K2D](5K2D)   Batyuk et al., [@B5]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 No                     None                  2.8                  [5JTB](5JTB)   Melnikov et al., [@B46]
                         Inactive                   Antagonist         8D1[^b^](#TN2){ref-type="table-fn"}     BRIL                 No                     None                  3.5                  [5UIG](5UIG)   Sun et al., [@B64]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 No                     None                  3.2                  [5UVI](5UVI)   Martin-Garcia et al., [@B45]
                         Inactive                   Antagonist         Caffeine                                BRIL                 Yes                    None                  2.1                  [5MZP](5MZP)   Cheng et al., [@B14]
                         Inactive                   Antagonist         Theophylline                            BRIL                 Yes                    None                  2.0                  [5MZJ](5MZJ)   Cheng et al., [@B14]
                         Inactive                   Antagonist         PSB36                                   BRIL                 Yes                    None                  2.8                  [5N2R](5N2R)   Cheng et al., [@B14]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 Yes                    None                  2.1                  [5NLX](5NLX)   Weinert et al., [@B72]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 Yes                    None                  2.0                  [5NM2](5NM2)   Weinert et al., [@B72]
                         Inactive                   Inverse agonist    ZM241385                                BRIL                 Yes                    None                  1.7                  [5NM4](5NM4)   Weinert et al., [@B72]
                         Intermediate-active        Agonist            UK-432097                               T4L                  No                     None                  2.7                  [3QAK](3QAK)   Xu et al., [@B75]
                         Intermediate-active        Agonist            Adenosine                               None                 Yes                    None                  3.0                  [2YDO](2YDO)   Lebon et al., [@B40]
                         Intermediate-active        Agonist            NECA                                    None                 Yes                    None                  2.6                  [2YDV](2YDV)   Lebon et al., [@B40]
                         Intermediate-active        Agonist            CGS21680                                None                 Yes                    None                  2.6                  [4UG2](4UG2)   Lebon et al., [@B38]
                         Intermediate-active        Agonist            CGS21680                                None                 Yes                    None                  2.6                  [4UHR](4UHR)   Lebon et al., [@B38]
                         Active                     Agonist            NECA                                    None                 No                     Mini-G~s~             3.4                  [5G53](5G53)   Carpenter et al., [@B12]

*Covalently bound antagonist*.

*Ligand nomenclature as used in the PDB*.

In this review we consolidate and analyze all of the structural information published during the past decade, which provides a near complete picture of A~2A~R activation. We compare the binding mode of antagonists, including the widely consumed stimulant caffeine (Doré et al., [@B19]; Cheng et al., [@B14]), and agonists, including the endogenous ligand adenosine (Lebon et al., [@B40]). We highlight the agonist-induced conformational changes that activate A~2A~R (Lebon et al., [@B40]; Xu et al., [@B75]), and the cooperative conformational changes induced by G protein coupling (Carpenter et al., [@B12]). Finally, we compare A~2A~R with the recently solved structures of A~1~R (Cheng et al., [@B14]; Glukhova et al., [@B26]) and discuss the current evidence for the molecular basis of ligand binding specificity in different AR subtypes.

A~2A~R crystallization: selection of different conformational states {#s2}
====================================================================

GPCRs are challenging targets for structural studies for three main reasons. First, flexibility and conformationally dynamics play a central role in receptor activation by maintaining a dynamic equilibrium between different conformational states (Kobilka and Deupi, [@B35]). Ligand binding is often insufficient to trap the receptor in a distinct conformation (Manglik et al., [@B44]; Ye et al., [@B76]), which can perturb the growth of crystals that diffract to high resolution (Cherezov et al., [@B15]; Warne et al., [@B71]; Tate and Schertler, [@B65]). Second, GPCRs are highly unstable upon extraction from the membrane by detergent solubilization, which makes purification of the receptors both technically challenging and inefficient (Serrano-Vega et al., [@B60]). Third, class A receptors are compact proteins that typically have only minimal hydrophilic surface area capable of forming crystal contacts. Structure determination of virtually all GPCRs, including A~2A~R, has therefore required the development of novel protein engineering strategies (discussed below), crystallization techniques, including LCP (Landau and Rosenbusch, [@B36]; Xu et al., [@B75]; Caffrey, [@B7]), and data collection methods, including the use of micrometer-sized X-ray beams (Moukhametzianov et al., [@B47]) or serial crystallography (Weinert et al., [@B72]), in order to obtain well-diffracting crystals and collect high resolution diffraction data.

The first structure of A~2A~R was solved bound to the inverse agonist ZM241385 at 2.6 Å resolution (Jaakola et al., [@B30]). This structure was facilitated by a combined approach of using a high affinity ligand, which locks the receptor in its inactive state, and by replacing the third intracellular loop (ICL3) with a T4 lysozyme (T4L) fusion protein (Rosenbaum et al., [@B55]), which increases the hydrophilic surface area available for crystal contact formation (Figure [1A](#F1){ref-type="fig"}). This fusion protein strategy was subsequently modified to utilize apocytochrome b~562~RIL (BRIL) instead of T4L (Liu et al., [@B41]), which resulted in the solution of seven additional structures of A~2A~R bound to ZM241385 ranging in resolution from 3.2 to 1.8 Å (Liu et al., [@B41]; Batyuk et al., [@B5]; Martin-Garcia et al., [@B45]; Melnikov et al., [@B46]), and one structure bound to the antagonist 8D1 (Sun et al., [@B64]) (Table [1](#T1){ref-type="table"}). Conformational thermostabilization, which utilizes alanine scanning mutagenesis to identify point mutations that stabilize the receptor in a particular conformational state and increase its thermostability in detergent (Magnani et al., [@B43], [@B42]), was also applied to solve the structure of A~2A~R bound to ZM241385 (Doré et al., [@B19]). The construct A~2A~R-StaR2 contained eight thermostabilizing mutations (A54L^2.52^, T88A^3.36^, R107A^3.55^, K122^4.43^, L202A^5.63^, L235A^6.37^, V239A^6.41^, and S277A^7.42^; superscripts refer to Ballesteros--Weinstein numbering) (Ballesteros and Weinstein, [@B1]) that increased the stability of the receptor in the detergent dodecylmaltoside (DDM) by \~18°C. A~2A~R-StaR2 has since been crystallized bound to four different antagonists XAC, caffeine, T4G and T4E (Doré et al., [@B19]; Congreve et al., [@B18]). Conformational thermostabilization has also been used in combination with a BRIL fusion protein to facilitate the crystallization of A~2A~R bound to the antagonists 6DY, 6DZ, 6DX, 6DV, ZM241385, caffeine, theophylline, and PSB36 (Segala et al., [@B59]; Cheng et al., [@B14]). Furthermore, ZM241385-bound A~2A~R has been co-crystallized in complex with an antibody F~ab~ fragment (Fab2823), which acts as an intracellular inverse agonist locking the receptor in its inactive conformation, and also helps to increase the hydrophilic protein surface available for crystal contact formation (Figure [1B](#F1){ref-type="fig"}) (Hino et al., [@B29]).

![Protein engineering strategies used for the selection and crystallization of distinct A~2A~R conformations. **(A)** Crystal structure of A~2A~R (colored green) in the inactive conformation bound to the inverse agonist ZM241385 (shown as spheres, carbon atoms colored orange) with T4 lysozyme (T4L; colored blue) fused between the intracellular ends of H5 and H6 (PDB: [3EML](3EML)) (Jaakola et al., [@B30]). The T4L fusion protein has also been substituted with apocytochrome b~562~RIL (BRIL; not shown) (Liu et al., [@B41]). **(B)** Structure of A~2A~R in the inactive conformation bound to ZM241385 (shown as spheres, carbon atoms colored orange) and an antibody F~ab~ fragment (colored cyan) that acts as an intracellular inverse agonist (PDB: [3VG9](3VG9) and [3VGA](3VGA)) (Hino et al., [@B29]). **(C)** Crystal structure of thermostabilized A~2A~R-GL26 in the intermediate-active conformation bound to the agonist adenosine (shown as spheres, carbon atoms colored magenta), the four thermostabilizing mutations (L48A^2.46^, A54L^2.52^, T65A^2.63^, and Q89A^3.37^) are shown as spheres and their carbon atoms colored yellow (PDB: [2YDO](2YDO)) (Lebon et al., [@B40]). In the expanded view the residues with which the thermostabilizing mutations interact (distance \<4 Å) are shown as sticks. Conformational thermostabilization has facilitated the crystallization of A~2A~R in both the agonist- and antagonist- bound conformations. **(D)** Structure of A~2A~R in the active conformation bound to NECA (shown as spheres, carbon atoms colored light pink) and an engineered G protein mini-G~s~ (colored brown; PDB: [5G53](5G53)) (Carpenter et al., [@B12]). Figures were prepared using PyMOL (PyMOL™ Molecular Graphics System, Version 1.8.6.0).](fphar-08-00898-g0001){#F1}

The first agonist bound structure of A~2A~R was solved in complex with the synthetic agonist UK-432097, using the T4L fusion strategy (Xu et al., [@B75]). This ligand is large, approximately three times the molecular weight of adenosine, and imparts a significant increase in thermostability to the receptor. Crystallization of A~2A~R bound to smaller less stabilizing agonists required the application of the conformational thermostabilization methodology (Figure [1C](#F1){ref-type="fig"}). In this case the receptor was thermostabilized in the presence of the agonist NECA, and four mutations (L48A^2.46^, A54L^2.52^, T65A^2.63^, and Q89A^3.37^) were combined in the final construct (A~2A~R-GL26) (Lebon et al., [@B37]). The stability of A~2A~R-GL26 was \~16°C higher than the wild type receptor in DDM, which facilitated structure determination of the receptor in complex with the small agonists adenosine and NECA (Lebon et al., [@B40]), as well as the larger CGS21680 (Lebon et al., [@B38]). All four agonist-bound structures adopted a conformation that was different from the inactive state, but that did not fully resemble the active state of the β~2~ adrenergic receptor (β~2~AR) in complex with heterotrimeric G~s~ (Rasmussen et al., [@B54]), this conformation was therefore defined as the intermediate-active state (Lebon et al., [@B40]). Interestingly, the high affinity agonist UK-432097 was sufficiently stabilizing to allow the crystallization of non-thermostabilized A~2A~R in the intermediate-active state. This is likely due to the large size of the ligand, which results in it forming more extensive molecular contacts with the receptor, in particular UK-432097 forms four additional direct hydrogen bonds with A~2A~R compared to adenosine. In the case of small low affinity agonists, such as adenosine, conformational thermostabilization was absolutely necessary to facilitate structured determination.

The agonist-bound A~2A~R structures exhibited some characteristics of the active receptor (Lebon et al., [@B39]), however stabilizing the fully active conformation requires simultaneous binding of the agonist and G protein or a functional mimetic (Rasmussen et al., [@B52],[@B54]). Co-crystallization of GPCRs in complex with heterotrimeric G proteins is the ideal case for characterizing receptors in their active state, however this approach is challenging, due in part to the large size and conformationally dynamic nature of the G protein (Westfield et al., [@B73]). The development of nanobodies that act as surrogates of heterotrimeric G proteins has proved to be a powerful approach to crystallize receptors in their active conformation (Steyaert and Kobilka, [@B62]), however the disadvantage of this method is that nanobodies do not recapitulate the native GPCR--G protein interface. Structure determination of A~2A~R in its active conformation was achieved using a recently developed minimal G protein, which is composed of a single engineered domain from the Gα~s~ subunit (Figure [1D](#F1){ref-type="fig"}) (Carpenter and Tate, [@B8], [@B10],[@B11]). This mini G protein (mini-G~s~) sufficiently stabilized NECA-bound A~2A~R in its fully active conformation to facilitate crystallization and structure determination at 3.4 Å resolution (Carpenter et al., [@B12]). This approach has now been applied to most heterotrimeric G proteins (Nehmé et al., [@B50]) and should play an important role solving high-resolution structures of other GPCRs in their active state (Strege et al., [@B63]).

Structural determinants of A~2A~R ligand binding and selectivity {#s3}
================================================================

The orthosteric binding site of A~2A~R can be defined by the residues involved in binding the endogenous agonist adenosine and the naturally occurring antagonist caffeine (see Figure [2](#F2){ref-type="fig"} for the ligand structures and atom numbering, and Table [2](#T2){ref-type="table"} for A~2A~R-ligand contacts). Adenosine and caffeine share a common xanthine moiety that in both cases establishes van der Waals interactions with M177^5.38^, M270^7.35^ and I274^7.39^, and a π-stacking interaction with the aromatic ring of F168, which is part of the helical portion of extracellular loop 2 (ECL2; Figures [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}) (Doré et al., [@B19]; Lebon et al., [@B40]; Cheng et al., [@B14]). N253^6.55^ forms hydrogen bonds with either the amine groups at positions C6 and N7 of the adenine moiety of adenosine (Lebon et al., [@B40]) or O11/O13 from the xanthine heterocycle of caffeine, for which two distinct binding orientations have been observed (Cheng et al., [@B14]). The ribose moiety of adenosine forms van der Waals interactions with V84^3.32^, L85^3.33^, T88^3.36^, W246^6.48^, and L249^6.51^; these residues form similar contacts with many antagonist. The main difference between the adenosine- and caffeine-binding modes is the formation of hydrogen bonds from the hydroxyl groups at positions C2 and C3 of the ribose moiety of adenosine to S277^7.42^ and H278^7.43^. The recent high-resolution structure of A~2A~R bound to caffeine (2.10 Å) did reveal a water-mediated contact between H278^7.43^ and O11 of caffeine (Cheng et al., [@B14]). However, the presence of this water molecule highlights the difference in the distance between these atoms compared to the adenosine-bound state, where a direct interaction is observed. This distance is reduced concomitantly with the conformational changes in H3 and H7 associated with agonist binding to the receptor (Figure [5](#F5){ref-type="fig"}) (Lebon et al., [@B39]). All agonists that have been co-crystallized with A~2A~R engage H3 through T88^3.36^ and H7 through S277^7.42^/H278^7.43^ (Table [2](#T2){ref-type="table"}). Some antagonists do interact with either T88^3.36^ or S277^7.42^/H278^7.43^, but never at the same time, which suggests that the simultaneous engagement of these residues in H3 and H7 may be a key determinant of agonist activity.

![Two dimensional structures of the endogenous A~2A~R agonist adenosine and the naturally occurring antagonist caffeine. The atom numbering indicated is used in the text to describe the binding of these ligands and their derivatives to A~2A~R.](fphar-08-00898-g0002){#F2}

###### 

A~2A~R-ligand interactions.

  **Secondary structure element**   **A~2A~R residue**              **Ligand (agonist/antagonist)**                                                                                                                                    
  --------------------------------- ------------------------------- --------------------------------- ------------------------------- ------------------------------- -- -- -- -- -- -- -- -- -- -- -- ------------------------------- --
  H1                                Y9                                                                                                                                                                                                 
  H2                                A63                                                                                                                                                                                                
  I66                                                                                                                                                                                                                                  
  S67                                                                                                                                                                                                                                  
  H3                                A81                                                                                                                                                                                                
  V84                                                                                                                                                                                                                                  
  L85                                                                                                                                                                                                                                  
  T/A88                             ![](fphar-08-00898-i0001.jpg)   ![](fphar-08-00898-i0001.jpg)     ![](fphar-08-00898-i0001.jpg)   ![](fphar-08-00898-i0001.jpg)                                    ![](fphar-08-00898-i0001.jpg)   
  Q/A89                                                                                                                                                                                                                                
  I92                                                                                                                                                                                                                                  
  ECL2                              L167                                                                                                                                                                                               
  F168                                                                                                                                                                                                                                 
  E169                                                                                                                                                                                                                                 
  M174                                                                                                                                                                                                                                 
  H5                                M177                                                                                                                                                                                               
  N181                                                                                                                                                                                                                                 
  H6                                W246                                                                                                                                                                                               
  L249                                                                                                                                                                                                                                 
  H250                                                                                                                                                                                                                                 
  I252                                                                                                                                                                                                                                 
  N253                                                                                                                                                                                                                                 
  T256                                                                                                                                                                                                                                 
  ECL3                              H264                                                                                                                                                                                               
  A265                                                                                                                                                                                                                                 
  H7                                P266                                                                                                                                                                                               
  L267                                                                                                                                                                                                                                 
  M270                                                                                                                                                                                                                                 
  Y271                                                                                                                                                                                                                                 
  I274                                                                                                                                                                                                                                 
  S/A277                                                                                                                                                                                                                               
  H278                                                                                                                                                                                                                                 

*A~2A~R residues that directly interact with each ligand (distances \< 4 Å) are indicated by filled cells and colored according to the ligand type with which they interact (agonists only, red; antagonists only, blue; both agonists and antagonists, gray). Residues F168^ECL2^, M177^5.38^, L249^6.51^, N253^6.55^ and I274^7.39^ interact with all agonists and antagonists for which structures have been solved and are indicated by filled cells colored green. T88^3.36^ interacts with all agonists for which structures have been solved and is a key residue in agonist-induced receptor activation, however since it also interacts with the antagonist 8D1 (discussed in the text) it is indicated by hatched cells colored red. The secondary structure element in which each residue is located is shown in the left hand column (H, transmembrane helix; ECL, extracellular loop). The PDB codes of the A~2A~R structures used for analysis are shown in parentheses next to each ligand. Note that several of the A~2A~R structures contain thermostabilizing mutations, including T88A/S277A (caffeine, theophylline, T4G, T4E, XAC, 6DX, 6DZ, 6DY, 6DV, PSB36) and Q89A (adenosine, NECA and CGS21680)*.

![High-resolution view of the agonist-binding site of human A~2A~R. Four different agonists have been co-crystallized with A~2A~R in the intermediate-active conformation. The receptor is shown as cartoons and colored gray, residues and side chains that interact with the ligand are shown as sticks and colored by element (carbon, gray; nitrogen, blue; oxygen, red; sulfur, yellow). The ligands are shown as sticks and their carbon atoms are colored to match their labels, PDB codes are shown in the figure. Polar contacts are represented as dashed lines and water molecules are shown as red spheres.](fphar-08-00898-g0003){#F3}

![High-resolution view of the antagonist- or inverse agonist- binding site of human A~2A~R. Twelve different antagonists or inverse agonists have been co-crystallized with A~2A~R, in the inactive conformation. The receptor is shown as cartoons and colored gray, residues and side chains that interact with the ligand are shown as sticks and colored by element (carbon, gray; nitrogen, blue; oxygen, red; sulfur, yellow). The ligands are shown as sticks and their carbon atoms are colored to match their labels, PDB codes are shown in the figure. Polar contacts are represented as dashed lines and water molecules are shown as red spheres. Note that for caffeine the two distinct binding orientations that were observed in the structure are overlaid.](fphar-08-00898-g0004){#F4}

![Ligand-induced activation of A~2A~R. **(A)** Conformational changes associated with agonist-induced transition from the inactive state (colored cyan) to the intermediate-active state (colored yellow; PDB: [2YDV](2YDV)) (Lebon et al., [@B40]). Two different inactive state structures were used for the alignments, the extracellular view uses 4EIY (Liu et al., [@B41]) because it is the highest resolution non-thermostabilized structure available, the intracellular view uses 3PWH (Doré et al., [@B19]) because it was crystallized without a fusion protein in ICL3. The extracellular view shows the 1--2 Å inward shifts in the ends of H1, H2, and H3 (indicated by a red arrows), the 2 Å translocation of H3 along its axis (indicated by a dashed red arrow), and the inward bulge in H5 (indicated by a red asterisk). The inverse agonist ZM241385 (colored cyan) and agonist NECA (colored yellow) are shown as sticks. The intracellular view shows the combined rotational and lateral movements in H5, H6, and H7 (indicated by curved red arrows). H5 and H6 are displaced outwards by 7 and 5 Å, respectively, while H7 moves inwards in by 4 Å. **(B)** Conformational changes associated with G protein-induced transition from the intermediate-active state (colored yellow; PDB: [2YDV](2YDV)) (Lebon et al., [@B40]) to the active state (colored green; PDB: [5G53](5G53)) (Carpenter et al., [@B12]). No significant changes are observed on the extracellular side of the receptor, and the position of NECA (shown as sticks) is essentially identical in both states (Carpenter et al., [@B12]). On the intracellular side of the receptor an outward movement of H6 by 14 Å (indicated by a red arrow) is required to accommodate binding of mini-G~s~ (colored magenta). H5 moves inwards by 5 Å (indicated by a red arrow) and forms direct contacts the α5 helix of mini-G~s~. H7 undergoes a rotation, without significant lateral movement (indicated by a curved and dashed red arrow), which reorients the H7-H8 boundary to interact with the C-terminus of mini-G~s~ (Carpenter et al., [@B12]). Note that for clarity, ECL2 has been omitted from the extracellular view of all alignments.](fphar-08-00898-g0005){#F5}

Structures of A~2A~R have been solved in complex with three high-affinity synthetic agonists NECA, CGS21680 and UK-432097 (Lebon et al., [@B40], [@B38]; Xu et al., [@B75]). These agonists share a core adenosine moiety, the binding mode of which is very similar to adenosine itself, with the ribose group establishing hydrogen bonds with S277^7.42^ and H278^7.43^. For all three ligands the N-ethylcarboxyamido tail at position C5′ of the ribose ring extends deep into the binding pocket. The nitrogen and oxygen atoms form polar contacts with T88^3.36^ and H250^6.52^, respectively, and the substituent is further stabilized by van der Waals interactions with N181^5.42^, W246^6.48^ and to a lesser extent Q/A^3.37^. In contrast, the OH group at this position of adenosine interacts with N181^5.42^ and H250^6.52^ through water-mediated interactions and M177^5.38^ through a van der Waals interaction. The major difference between the binding mode of these agonists can be seen in the extracellular loops of the receptor. NECA and adenosine are both stabilized by a hydrogen bond with E169^ECL2^ (Lebon et al., [@B40]); this residue also forms a salt bridge with H264^ECL3^, which closes the top of the binding pocket and is known to affect ligand binding kinetics (Guo et al., [@B27]; Segala et al., [@B59]). CGS21680 takes advantage of similar hydrogen bond between the amine group at position C6 of adenine moiety and E169^ECL2^ (Lebon et al., [@B38]). The larger (2-carboxyethyl)phenylethylamino substituent at the C2 position protrudes outside the binding pocket and is stabilized by van der Waals interactions with E169^ECL2^, H264^ECL3^, and L267^7.32^ as well as a hydrogen bond with S67^2.65^. As a consequence, the extracellular end of H2 is displaced inward compared to other agonist-bound structures, reducing the volume of the binding pocket. UK-432097 has two substituents on the adenine moiety, that make it an even larger molecule than CGS21680. The consequence is that the bulky 2-(3-\[1-(pyridine-2-yl)piperidin-4-yl\]ureido)ethylcarboxamido substitution at position C2 displaces ECL3 away from the binding pocket, which induces rotamer changes in E169^ECL2^ and H264^ECL3^ and breaks the salt bridge between these side chains (Xu et al., [@B75]). The urea group forms two hydrogen bonds with E169^ECL2^ as well as a hydrogen bond and van der Waals interactions with Y271^7.36^ on its opposite side. The pyridinyl-piperidine group, which extends furthest from the binding pocket, is stabilized by van der Waals interactions with L267^7.32^ and H264^ECL3^.

Like agonists, antagonists can exploit subsidiary binding sites by expanding their contact surface outside the orthosteric binding pocket. Starting with ZM241385, the trizolotriazine ring occupies the orthosteric binding site, and is surrounded by F168^ECL2^, L249^6.51^, M270^7.35^, I274^7.39^. Two residues, E169^ECL2^ and N253^6.55^, form hydrogen bonds with the amine group of the ZM241385 heterocycle and an additional hydrogen bond is established between N253^6.55^ and the oxygen of the furan ring. The formation of van der Waals interactions with M177^5.38^, W246^6.48^, L249^6.51^, and H250^6.52^ stabilize H5 and H6 against the furan ring. ZM241385 explores the chemical space outside the orthosteric site by taking advantage of the cavity on the extracellular surface of the receptor. Two distinct orientations have been observed for the phenol ring of ZM241385, in the first conformation the salt bridge between E169^ECL2^ and H264^ECL3^ is intact and the phenol ring forms van der Waals interactions with H264^ECL3^, L267^7.32^ and M270^7.35^ (Jaakola et al., [@B30]). Interestingly, the phenylethylamine group of ZM241385 adopts a binding mode similar to the (2-carboxyethyl)phenylethylamino substituent of CGS21680 (Lebon et al., [@B38]). The second conformation was observed in a thermostabilized receptor structure where the salt bridge between E169^ECL2^ and H264^ECL3^ is broken (Doré et al., [@B19]). In this case the phenol moiety is pointing toward H1 and H2 engaging S67^2.65^, Y271^7.36^, and I274^7.39^ through van der Waals interactions and A63^2.61^ through a hydrogen bond. Both Y9^1.35^ and Y271^7.36^ sidechains adopt different rotamers in order to accommodate the phenol substituent in this pose, demonstrating that this subsidiary pocket is conformationally malleable. The xanthine derivative XAC occupies the orthosteric pocket with the xanthine ring adopting a similar position to caffeine and the trizolotriazine heterocycle of ZM241385 (Doré et al., [@B19]). However, the xanthine core is branched at position N1 and N3; the N3 propyl substituent forms van der Waals interactions with I66^2.64^ and A81^3.29^ that are not observed for ZM241385. On the extracellular surface of the receptor the phenoxy-acetamide tail of XAC adopts a pose that is similar to the phenol group of ZM241385 in the thermostabilized receptor structure and is engaged by S67^2.65^, L267^7.32^, M270^7.35^, Y271^7.36^, and I274^7.39^. However, none of these interactions are unique to XAC since they are all observed for ZM241385 in either of its two poses. The recent structure of 8D1 (also known as compound-1) bound to A~2A~R provides another example of a ligand that exploits this subsidiary binding site (Sun et al., [@B64]). The methoxy phenyl substituent of 8D1 occupies the extracellular pocket formed by Y9^1.35^, A63^2.61^, I66^2.64^, S67^2.65^, L267^7.32^, M270^7.35^, Y271^7.36^, and I274^7.39^ in a similar way to XAC and ZM241385. In this case a unique interaction is observed between 8D1 and Y9^1.35^ that is not observed for any other ligand (Table [2](#T2){ref-type="table"}). Thus, several different ligands and chemical substituents have been shown to take advantage of the subsidiary binding pocket located between H1, H2, and H7 on the extracellular surface of the receptor.

Cavities identified from high-resolution crystal structures provide valuable information for structure-based drug discovery. This can be best illustrated by the study of Congreve et al. who have reported the discovery of 1,2,4-triazine derivatives as A~2A~R antagonists by exploiting structural data (Congreve et al., [@B18]). The authors optimized a series of compounds and hypothesized that 1,2,4-triazine derivatives may occupy the same area of the binding pocket as the ribose moiety of agonists. Solution of the corresponding ligand--receptor structures showed that the triazine ring of T4E or T4G sits in a pocket similar to other ligands, and forms van der Waals interactions with F168^ECL2^ and two hydrogen bonds with N253^6.55^. The phenol substituent forms van der Waals interactions with L85^3.33^, M177^5.38^, W246^6.48^ L249^6.51^, and H250^6.52^. As predicted the dimethyl-pyridine group of T4G occupies the ribose pocket and the phenolic hydroxyl group of T4E establishes a hydrogen bond with H278^7.43^, but importantly the ligands retain their antagonistic properties.

Crystallographic studies have also highlighted the role that ECL2 and ECL3 play in ligand binding, specifically the effect of the salt bridge between E169^ECL2^ and H264^ECL3^ (Lebon et al., [@B38]; Guo et al., [@B27]; Segala et al., [@B59]). These two residue as well as the salt bridge that they form, stabilize several ligands in the binding pocket, as described above for ZM241385. The phenol ring of the ZM241385 has recently been replaced by a set of larger substitutions and their structures have been solved in complex with A~2A~R at high resolution (Segala et al., [@B59]). The substitutions were reported to affect the residence time of the ligands, with the ligand 6DV (also known as 12x) displaying the slowest off-rate. This observation is also in agreement with the agonist-bound structures where the salt bridge closes the binding site for adenosine, NECA and CGS21680 (Lebon et al., [@B40], [@B38]). Mutation of either E169^ECL2^ or H264^ECL3^ has been shown to impair the potency of NECA whereas only mutation of H264^ECL3^ affected CGS21680 (Lebon et al., [@B38]). The lower potency of agonists on these mutant receptors might be a consequence of a faster off-rate in absence of the salt bridge, however it appears that the stabilizing effect of the salt bridge can be compensated for by extended molecular contact formed by large molecules, such as CGS21680.

Ligand-induced activation of A~2A~R {#s4}
===================================

GPCRs exist in dynamic equilibrium between several discrete conformational states that are separated by energy barriers (Manglik et al., [@B44]; Ye et al., [@B76]). The inactive and active states are well-conserved between GPCRs (Rosenbaum et al., [@B56]; Carpenter and Tate, [@B9]), however a number of intermediate conformations have been identified that appear to be more divergent (Lebon et al., [@B40]; Xu et al., [@B75]; White et al., [@B74]; Manglik et al., [@B44]; Ye et al., [@B76]). Agonist binding to the receptor is one of the key events required to overcome the energy barrier of activation and increase occupancy of the conformational state(s) that are capable of binding heterotrimeric G proteins (Manglik et al., [@B44]; Ye et al., [@B76]; Prosser et al., [@B51]). A~2A~R is one of the only receptors for which an intermediate-active agonist-bound state has been crystallized (Lebon et al., [@B40]; Xu et al., [@B75]). This structure has provided unique insight into the molecular changes that occur during two key activation events, namely agonist-induced transition from the inactive to intermediate-active state and G protein-induced transition from the intermediate-active to active state. The structures used for comparison are the inactive state bound to the inverse agonist ZM241385 (Doré et al., [@B19]; Liu et al., [@B41]), the intermediate-active state bound to the agonist NECA (Lebon et al., [@B40]) and the active state bound to NECA and mini-G~s~ (Carpenter et al., [@B12]), see Figure [5](#F5){ref-type="fig"}. Agonist binding to A~2A~R triggers a series of conformational changes, most notably within the ligand-binding pocket and on the intracellular side of the receptor (Figure [5A](#F5){ref-type="fig"}). In the ligand binding pocket the most significant changes are a 2 Å translocation of H3 along its axis that is necessary to prevent steric clashes of V84^3.32^ and L85^3.33^ with NECA, the formation of contacts between the ribose moiety of the agonist and residues S277^7.42^ and H278^7.43^ in H7 that are completely absent in the inverse agonist-bound state, and an inward bulge in H5 that disrupts the local helix geometry and shifts C185^5.46^ toward the core of the receptor by 4 Å (Lebon et al., [@B40]). Notably, the bulge in H5 has a knock-on effect on the position of H250^6.52^, which is shifted toward the ligand by 2 Å, a movement that would be sterically forbidden if the inverse agonist were bound (Lebon et al., [@B40], [@B39]; Xu et al., [@B75]). This bulge is also observed in other GPCR structures suggesting it is one of the key event in activation (Venkatakrishnan et al., [@B67]). Agonist binding causes only subtle conformational changes on the extracellular side of the receptor, including 1-2 Å inward shifts in the ends of H1, H2, and H3. More significant changes are observed on the intracellular side, which are thought to prime the receptor for G protein coupling (Venkatakrishnan et al., [@B66]), specifically combined rotations and lateral movements in the cytoplasmic ends of H5, H6, and H7, outwards by 7 and 5 Å for H5 and H6, respectively, and inwards by 4 Å for H7 (Figure [5A](#F5){ref-type="fig"}) (Lebon et al., [@B40]; Xu et al., [@B75]). The ionic lock between R102^3.50^ and E228^6.30^, which is often engaged in inactive GPCR structures, is broken by the reorientation of H6.

Sodium ions (Na^+^) act as negative allosteric modulators of many class A GPCRs, typically stabilizing the ligand-free and antagonist-bound states, thereby imposing an energy barrier on receptor activation (Katritch et al., [@B33]). The high-resolution model of A~2A~R in its inactive state was the first GPCR structure to reveal the mode of Na^+^ binding (Liu et al., [@B41]). In A~2A~R the Na^+^-binding pocket is composed of residues D52^2.50^, S91^3.39^, T88^3.36^, W246^6.48^, N280^7.45^, and S281^7.46^; both D52^2.50^ and S91^3.39^ form direct polar interactions with Na^+^, whereas interactions with the other residues are mediated through a network of ordered water molecules (Liu et al., [@B41]; Gutiérrez-de-Terán et al., [@B28]). The conformational changes induced by agonist binding, particularly the rotation and inward shift of H7 and the outward shift of H6, cause the Na^+^-binding pocket to collapse, potentiating the displacement of Na^+^, thereby allowing the agonist to overcome the negative allosteric effect of Na^+^ and activate the receptor (Gutiérrez-de-Terán et al., [@B28]). Interestingly, the intermediate-active conformation is not observed in crystal structures of agonist-bound β~1~AR (Warne et al., [@B70]) or β~2~AR (Rosenbaum et al., [@B57]). Recent ^19^F nuclear magnetic resonance (^19^F NMR) studies have confirmed the existence of an additional active-like state in A~2A~R compared to β~2~AR (Manglik et al., [@B44]; Ye et al., [@B76]; Prosser et al., [@B51]), which may correlate with the intermediate-active conformation observed in the crystal structures, thus highlighting differences in the energy landscape of activation between these receptors.

In contrast to the widely distributed effects of agonist binding, G protein-induced conformational changes are confined to the intracellular side of the receptor (Figure [5B](#F5){ref-type="fig"}). G protein coupling has been reported to increase the agonist-binding affinity of A~2A~R between 10- and 40-fold (Murphree et al., [@B49]; Carpenter et al., [@B12]), yet it is striking that the conformation of the residues in the ligand-binding pocket and the position of the agonist are essentially identical in both the intermediate-active and active states (Carpenter et al., [@B12]). The most likely explanation is that in the intermediate-active structure the ligand-binding pocket has already adopted the high-affinity conformation (Carpenter et al., [@B12]). However, it cannot be discounted that the relatively small increase in the agonist-binding affinity of A~2A~R does not result from direct changes to the ligand-binding pocket, for example, a reduction in the conformational dynamics of the receptor caused by G protein binding could decrease the off-rate of the agonist, thus increasing its affinity (Carpenter and Tate, [@B9]). On the intracellular side of the receptor the pivotal event is a 14 Å outward movement of the cytoplasmic end of H6 to accommodate binding of the α5 helix from mini-G~s~. The outward movement of H6 triggers both a 5 Å inward movement of H5, positioning it to interact with the α5 helix of the G protein, and a rotation within H7 that reorients the H7-H8 boundary to form extensive contacts with the C-terminus of mini-G~s~ (Carpenter et al., [@B12]). These helix movements also result in reorientation of R102^3.50^, Y197^5.58^, and Y288^7.53^ side chains within the core of the receptor, which likely stabilizes the active state, and which is one of the signatures of a GPCR in its active conformation (Carpenter and Tate, [@B9]). It is clear that the intermediate-active state of A~2A~R is incompatible with G protein binding in its final orientation, i.e., that observed in the A~2A~R--mini-G~s~ structure (Carpenter et al., [@B12]), due to a large sterically forbidden clash between the α5 helix of mini-G~s~ and H6 of the receptor (Figure [5B](#F5){ref-type="fig"}). However, it is possible that the intermediate-active state of A~2A~R may be responsible for recognition of the G protein through an initial docking interaction, before cooperative conformational changes trigger nucleotide dissociation from the G protein and drive the receptor into its active conformation (Rasmussen et al., [@B54]; Flock et al., [@B20]; Carpenter et al., [@B12]).

Structural diversity of the adenosine receptor family {#s5}
=====================================================

The amino acid sequence of the four AR subtypes is relatively poorly conserved, A~2A~R shares only 49, 56, and 39% identity with A~1~R, A~2B~R, and A~3~R, respectively (aligned over residues 1-312 of A~2A~R). This means that, despite there being a wealth of structural data available for A~2A~R, it has proved challenging to homology model other AR subtypes with sufficient accuracy for structure-based drug design applications (Glukhova et al., [@B26]). It is only during the past year that structures of an AR other than A~2A~R have been published, namely two structures of A~1~R bound to the xanthine antagonists DU172 (Glukhova et al., [@B26]) and PSB36 (Cheng et al., [@B14]). The two A~1~R structures are closely related and align with an RMSD of 0.6 Å (over 235 Cα atoms), they also align well with the ZM241385-bound structure of A~2A~R (Liu et al., [@B41]), with RMSDs of 0.8 Å (over 238 Cα atoms) and 1.0 Å (over 234 Cα atoms) for the DU172- and PSB36- bound structures, respectively. The intracellular side of both A~1~R structures strongly resemble the ZM241385-bound A~2A~R structure (3PWH), which was crystallized without a fusion protein in ICL3 (Doré et al., [@B19]), and the ionic lock between residues R105^3.50^ and E229^6.30^ is engaged in both cases (Cheng et al., [@B14]; Glukhova et al., [@B26]). The organization of the sodium-binding site is also well-conserved between A~1~R and A~2A~R, which supports mutagenesis data that indicated the negative allosteric effect of sodium on A~1~R was mediated through this site (Barbhaiya et al., [@B4]), although neither A~1~R structure was of sufficient resolution to conclusively model the sodium ion.

The most striking differences between A~1~R and A~2A~R are the conformational variations in extracellular ends of H1, H2, H3, and H7 and the orientation of ECL2. In the DU172-bound structure H3 is displaced inwards by 4 Å, and H1, H2, and H7 are displaced outwards by 5, 4, and 4 Å, respectively (Figure [6A](#F6){ref-type="fig"}). The outward movements in H1, H2, and H7 are required to accommodate the benzene sulfonate group of DU172, which is covalently linked to Y271^7.36^, and result in both the expansion of the orthosteric site and the formation of a secondary allosteric pocket (Glukhova et al., [@B26]). Direct comparison of A~1~R and A~2A~R bound to PSB36, which does not contain the benzene sulfonate substituent, also reveals a partial expansion of the orthosteric pocket (Cheng et al., [@B14]), indicating that this region of A~1~R is indeed more conformationally malleable than that of A~2A~R. Intriguingly, it has been suggested that the conformational rearrangements in H1, H2, and H3 in A~1~R may be a direct result of the different disulphide bond structure of ECL2 (Glukhova et al., [@B26]). In both A~1~R structures ECL2 adopts a similar conformation, which is different from that observed in any of the published A~2A~R structures (Figure [6B](#F6){ref-type="fig"}). The helical segment in ECL2 of A~1~R is extended by five residues and is positioned almost perpendicular to the transmembrane helices, compared to the near parallel arrangement in A~2A~R (Cheng et al., [@B14]; Glukhova et al., [@B26]). There is only a single disulphide bond in ECL2 of A~1~R compared to three within the same region of A~2A~R, which results in it adopting an extended conformation (Figure [6B](#F6){ref-type="fig"}). This appears to reduce conformational constraints on the extracellular ends of H2 and H3 allowing them to be displaced outwards, which in turn influences the positioning of H1. The displacement of H7 may also be linked to structural divergence in the extracellular loops, in this case a single amino acid truncation in ECL3 of A~1~R has been proposed to induce the outward tilt observed in the structures (Cheng et al., [@B14]; Glukhova et al., [@B26]).

![Structural diversity of the adenosine receptor family. **(A)** Extracellular view of the conformational differences between DU172-bound A~1~R (colored magenta; PDB: [5UEN](5UEN)) (Glukhova et al., [@B26]) and ZM241385-bound A~2A~R (colored cyan; PDB: [4EIY](4EIY)) (Liu et al., [@B41]). The extracellular ends of H1, H2 and H7 are displaced outwards by 5, 4, and 4 Å, respectively and H3 is displaced inwards by 4 Å (indicated by red arrows). The antagonist DU172 (shown as spheres) is covalently attached to Y271^7.36^ (shown as sticks) through a benzene sulfonate linkage. Note that for clarity, ECL2 has been omitted from the alignment. **(B)** Differential conformations of ECL1 (colored green) and ECL2 (colored blue) in A~1~R (colored magenta; PDB: [5UEN](5UEN)) (Glukhova et al., [@B26]) and A~2A~R (colored cyan; PDB: [4EIY](4EIY)) (Liu et al., [@B41]), disulphide bonds are shown as sticks. In A~1~R ECL2 adopts an extended conformation that is stabilized by a single disulphide bond (C80^3.25^-C169^ECL2^). In contrast, ECL2 from A~2A~R adopts a compact conformation that is stabilized by three disulphide bond, one of which (C77^3.25^-C166^ECL2^) is conserved in A~1~R. **(C)** Surface representation of the ligand-binding pocket (rendered as semi-transparent mesh) in A~1~R (colored blue; PDB: [5N2R](5N2R)) (Cheng et al., [@B14]) and A~2A~R (colored green; PDB: [5N2S](5N2S)) (Cheng et al., [@B14]), which highlights differences in both the topology of the orthosteric site and the binding orientation of PSB36 (shown as sticks). The butyl substituent at position N1 of the xanthine core of PSB36 fits into a channel between H3, H5, and H6 in A~1~R, this channel is constricted in A~2A~R due to the different orientation of L85^3.34^ (shown as sticks), which results in the ligand binding in a different orientation.](fphar-08-00898-g0006){#F6}

What do these structures tell us about the molecular determinants of ligand-binding specificity in different AR subtypes? First, sequence differences in the binding pocket do not appear to be the main determinant of ligand-binding specificity in ARs. The orthosteric binding pocket of A~1~R and A~2A~R in the PSB36-bound structures differ by only four residues V62^2.57^, N70^2.65^, E170^ECL2^, and T270^7.35^ (corresponding to A59^2.57^, S67^2.65^, L170^ECL2^, and M270^7.35^ in A~2A~R), and of these, only T/M270^7.35^ form direct contacts with the ligand (Cheng et al., [@B14]). Mutagenesis studies have shown that residue 270^7.35^ is important in ligand-binding specificity, introducing the T270M mutation into A~1~R resulted in decreased binding affinity of A~1~R-specific ligands and increased binding affinity of A~2A~R-specific ligands, the reverse effect was observed when the M270T mutation was introduced into A~2A~R (Cheng et al., [@B14]; Glukhova et al., [@B26]). However, the positioning of this residue on the extracellular end of H7, at the perimeter of the binding pocket, suggests its main role is to act as a "gatekeeper" that regulates ligand access to the orthosteric site (Glukhova et al., [@B26]). Second, the topology of the binding pocket appears to play a central role in ligand-binding specificity. As described above the disulphide bond structure of ECL1 and ECL2 in A~1~R increases mobility in H1, H2 and H3, which causes an expansion of the binding pocket that is required to accommodate the benzene sulfonate group of the A~1~R-selective ligand DU172 (Figure [6A](#F6){ref-type="fig"}) (Glukhova et al., [@B26]). Binding pocket topology is also the predominant factor in the differential binding modes of PSB36 between A~1~R and A~2A~R (Figure [6C](#F6){ref-type="fig"}). PSB36 binds 2 Å deeper in the orthosteric pocket of A~1~R due to the presence of a channel between H3, H5 and H6 that can accommodate the butyl substituent at position N1 of the xanthine core (Figure [6C](#F6){ref-type="fig"}) (Cheng et al., [@B14]). This channel is created by a 2 Å displacement of L88^3.34^ in A~1~R that appears to be the result of an upstream proline residue (P86^3.31^), which is located outside the binding pocket, distorting the helix geometry in this region of H3. A proline at this position is unique to A~1~R and helps to explain why substitutions at position N1 of the xanthine core contribute to A~1~R selectivity (Cheng et al., [@B14]). Thus, the amino acid sequence both inside and outside the ligand-binding site, the extracellular loop structure and the topology of the binding pocket play interconnected roles in governing the ligand binding affinity and kinetics that are ultimately responsible for the functional selectivity of AR subtypes.

Conclusion {#s6}
==========

A decade of research and innovation has culminated in the crystallization of more than 30 structures of human A~2A~R in complex with one inverse agonist, 11 antagonists and four agonists, as well as an engineered G protein. These structures represent the inactive, intermediate-active and active conformational states, and A~2A~R remains the only receptor for which this complete series of structures has been reported. Most of the structure were obtained using high affinity ligands, such as ZM241385, XAC, NECA, UK-432097, CGS21680. However, the application of conformational thermostabilization has also facilitated structure determination of the receptor in complex with lower affinity ligands, including the endogenous agonist adenosine and the natural plant-derived antagonists caffeine and theophylline. Structural characterization of the ligand-binding pocket of A~2A~R has provide novel insight into the binding modes of different classes of ligands; the ribose moiety has been identified as a key component of agonists that helps to stabilize the intermediate-active state before the receptor can adopt the fully active conformation upon G protein coupling. The chemical diversity of compounds co-crystallized with A~2A~R has also revealed how some ligands can exploit subsidiary binding sites on the extracellular surface of the receptor, as exemplified by the antagonists XAC, ZM241385, 8D1, T4G, and T4E and agonists CGS21680 and UK-432097.

High-resolution structures have not only provided a clear picture of the ligand-binding pocket, but have also highlighted the impact of receptor flexibility, notably in ECL2 and ECL3, on the mode and kinetics of ligand binding. Furthermore, the recently solved structures of A~1~R revealed that binding pocket topology and extracellular loop structure are two of the most important factors affecting the ligand binding specificity of different AR subtypes. These observations highlight the challenges of homology modeling GPCRs, since differential extracellular loop structures, global helix movements and changes in binding pocket topology are more difficult to model than amino acid substitutions within the orthosteric site. Thus, continued efforts to experimentally determine structures of all four AR subtypes in the three distinct activation states are essential to maximize the potential of structure based drug design for this family of receptors. Interestingly, despite the fact that all ARs are known to signal through G protein-independent pathways, no biased ligands have thus far been reported for A~2A~R (Verzijl and Ijzerman, [@B68]). Functional selectivity has now been observed in A~1~R, A~2B~R, and A~3~R (Gao et al., [@B24]; Baltos et al., [@B2],[@B3]), which suggests that biased ligands could also be developed for A~2A~R. However, it is also possible that subtle differences in the energy landscape and mechanism of A~2A~R activation may mean that biased signaling is less pronounced for this receptor. Therefore, at present A~2A~R is not an ideal model for studying functional selectivity, however structural insight from other GPCRs that have been co-crystallized with biased agonists, such as β~1~AR (Warne et al., [@B69]), may yet help to facilitate the design biased ligands for A~2A~R.

Finally, how will the wealth of high-quality structural data reported for A~2A~R shape the future of drug development for this receptor? Structural based design has already been used to develop novel A~2A~R antagonists, including a 1,2,4-triazine derivative that is a preclinical candidate for the treatment of Parkinson\'s disease (Congreve et al., [@B18]). Further application of this approach will likely result in the identification of additional novel compounds, both agonists and antagonists, and will also facilitate the derivatization and optimization of existing ligands. The identification of the subsidiary binding pocket on the extracellular surface of A~2A~R is an important step toward the design of allosteric modulators. Exploitation of this pocket has thus far been achieved using orthosteric ligands with large substituents that extend outside the orthosteric site, however in the future it may also be possible to target this region using purely allosteric ligands. Such compounds have the potential to modulate the properties of orthosteric ligands, and could thus be used to fine tune adenosine signaling through individual AR subtypes.
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